AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00777842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GTX™ Drug Eluting Coronary Stent System
Description: Drug eluting stent
Study NCT03763981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: prolene seton treatment
Description: patients with perianal fistulas will treated with seton placement by prolene thread
Study NCT03763981 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: silk seton treatment
Description: patients with perianal fistulas will treated with seton placement by silk thread
Study NCT03243019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rapamycin
Description: oral administration
Study NCT03243019 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: cervicofacial MRI
Study NCT03243019 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rapamycin dosage
Description: Biological dosage of Rapamycin level
Study NCT03677401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5mg Serlopitant Tablets
Description: Serlopitant Tablets
Study NCT03677401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablets
Description: Placebo Tablets
Study NCT02711787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: Robotic assisted passive mobilization (Gloreha, Idrogenet, Italy) and traditional rehabilitation.
Study NCT02711787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Physiotherapy and occupational therapy.
Study NCT02711787 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional rehabilitation
Description: Assisted stretching, shoulder and arm exercises, and functional reaching tasks
Study NCT01053910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: tablet of Ramipril once daily
Study NCT02711787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: traditional rehabilitation
Description: Assisted stretching, shoulder and arm exercises, and functional reaching tasks
Study NCT01500083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine at a dose of 100 mg/m2
Description: Bendamustine will be administered intravenously over 30 minutes.
Study NCT01500083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine at a dose of 120 mg/m2
Description: Bendamustine will be administered intravenous (i.v.) over 60 minutes.
Study NCT04664114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Ultrasound images of the fetus in the 28th week of pregnancy of the women in the intervention group were recorded. These images were shown to the woman through virtual reality glasses during the labor. Routine practices in the hospital were made to the women in the control group. VAS (Visual Analog Scale) was applied to women in both groups when cervical dilatation was 4 and 9 cm. Approximately two hours after giving birth (to allow mothers to breastfeed their babies and to stabilize the mother's vital signs), the Women's Perception of Supportive Care at Birth Scale (POBS) and Perinatal Anxiety Screening Scale (PASS) were administered.
Study NCT01562444 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood draw
Description: Annual blood draw at years 6 (Visit 18), 7 (Visit 19), 8 (Visit 20), 9 (Visit 21) and 10 (Visit 22)
Study NCT04491487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pre-operative counselling
Description: pre-operative Speech-Language Pathology (SLP) counselling before Total Laryngectomy
Study NCT01926535 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant of amniotic membrane grafts
Description: Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
Study NCT01926535 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic contact lenses
Description: Therapeutic contact lenses were applied in all patients included in the control group and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
Study NCT01177410 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsules once daily for 12 weeks
Study NCT01177410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine Granules 750 mg
Description: 750 mg mesalamine granules once daily for 12 weeks
Study NCT01177410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalamine Granules 1500 mg
Description: 1500 mg mesalamine granules once daily for 12 weeks
Study NCT03779607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Celtra Press
Description: new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing.
Study NCT03779607 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Celtra Press
Description: new class of zirconia-reinforced lithium silicate material available to labs for pressing. This unique material provides top aesthetics and is virtually impossible to tell apart from a natural tooth.~Celtra Press is a multiphase ceramic consisting of a glass matrix and lithium disilicate crystals having a crystal length of about 1.5 µm plus nano-scale lithium phosphate . In addition to Li2O and SiO2, Celtra Press contains about 10% zirconia (ZrO2), which is dissolved completely in the glass phase rather than in crystalline form. Celtra Press is characterized by a high strength of about 500 MPa and excellent flow properties during pressing.
Study NCT01025050 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrastromal Correction of Presbyopia
Description: On all patients an intrastromal pattern consisting of concentric rings will be applied.
Study NCT02200081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGN1703
Study NCT02200081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Usual Standard of Care according to local investigators practise, e.g. Treatment break continous treatment and other
Study NCT03791931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: oxidative stress measurement
Description: oxidative stress measurement
Study NCT02955693 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LAS41008 120 mg / Fumaderm® 120 mg
Description: Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
Study NCT01201499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal morphine
Description: a single dose of intrathecal morphine (ITM, 4 µcg/kg, or \~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.
Study NCT01201499 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous IV remifentanil
Description: a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
Study NCT03146364 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality - Virtual Interactive Supermarket
Description: SeeMe is a PC based, innovative, comprehensive, clinician-controlled exercise and diagnostic system. SeeMe is designed to aid the rehabilitation process, and track patients' progress.~Virtual Interactive Supermarket- one of the SeeMe Tasks, the user need to buy products by according to specific instruction
Study NCT00979511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: milk and exercise
Description: * milk fortified with 1000mg calcium or low-calcium milk~* weight-bearing exercise or passive exercise
Study NCT00609505 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine
Description: Telemedicine genetic counseling
Study NCT00609505 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Face-to-Face
Description: Face-to-face genetic counseling
Study NCT00248547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aprepitant
Description: Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
Study NCT00248547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: For Cyclophosphamide Total Body Irradiation(CyTBI) patients: Dexamethasone study drug 1 capsule PO daily, 1 hour prior to chemotherapy with aprepitant on total body irradiation(TBI) and cyclophosphamide chemotherapy days; For Busulfan Cyclophosphamide(BuCy) patients: Dexamethasone 1 capsule orally once daily, discontinue after last dose of chemotherapy.
Study NCT00248547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: dexamethasone
Description: For Cyclophosphamide Total Body Irradiation(CyTBI) patients: Dexamethasone study drug 1 capsule PO daily, 1 hour prior to chemotherapy with aprepitant on total body irradiation(TBI) and cyclophosphamide chemotherapy days; For Busulfan Cyclophosphamide(BuCy) patients: Dexamethasone 1 capsule orally once daily, discontinue after last dose of chemotherapy.
Study NCT00248547 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ondansetron
Description: For CyTBI patients: Ondansetron 8 mg orally evert 12 hours, begin 1 hour prior to first TBI dose and discontinue after last dose; then Ondansetron 8 mg IV every 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy; For BuCy patients: Ondansetron 8 mg orally every 6 hours, begin 1 hour prior to first busulfan dose and discontinue after last busulfan dose is given. then: Ondansetron 8 mg IV Q 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy
Study NCT00248547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ondansetron
Description: For CyTBI patients: Ondansetron 8 mg orally evert 12 hours, begin 1 hour prior to first TBI dose and discontinue after last dose; then Ondansetron 8 mg IV every 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy; For BuCy patients: Ondansetron 8 mg orally every 6 hours, begin 1 hour prior to first busulfan dose and discontinue after last busulfan dose is given. then: Ondansetron 8 mg IV Q 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy
Study NCT00248547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
Study NCT03590860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3322207
Description: Administered by SC injection
Study NCT03590860 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by SC injection
Study NCT04615507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JJVC Investigational Multifocal Contact Lens
Description: TEST Lens
Study NCT04615507 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dailies Total 1® Multifocal Contact Lens
Description: CONTROL Lens
Study NCT02992379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pivot splint
Description: A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of selfcuring acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe.
Study NCT02992379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: pivot splint
Description: A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of selfcuring acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe.
Study NCT02992379 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stabilizing splint
Description: A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
Study NCT02992379 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: stabilizing splint
Description: A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
Study NCT02852044 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rest
Description: Allowed to watch television or read for one hour prior to oral glucose tolerance test
Study NCT02852044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: One hour of cycling at 50% of maximal power output
Study NCT02852044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dorsal Hand Vein Cannulation (heated hand technique)
Study NCT02852044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dorsal Hand Vein Cannulation (heated hand technique)
Study NCT02852044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Venous Cannulation
Study NCT02852044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Venous Cannulation
Study NCT05181384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: isolated pelvic floor muscles training
Description: isolated pelvic floor muscles training was emphasized, consisting of both quick and sustained contractions.
Study NCT05181384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: isolated pelvic floor muscles training
Description: isolated pelvic floor muscles training was emphasized, consisting of both quick and sustained contractions.
Study NCT05181384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: comprehensive stabilization exercise program
Description: incorporated the contraction of PFMs with other spinal or extremity muscles
Study NCT05181384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: comprehensive stabilization exercise program
Description: incorporated the contraction of PFMs with other spinal or extremity muscles
Study NCT05181384 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: education of pelvic girdle
Description: educational session includes pelvic anatomy, mechanism of and risk factors for PPGP, and proper posture or body mechanism
Study NCT05181384 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: education of pelvic girdle
Description: educational session includes pelvic anatomy, mechanism of and risk factors for PPGP, and proper posture or body mechanism
Study NCT05181384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: education of pelvic girdle
Description: educational session includes pelvic anatomy, mechanism of and risk factors for PPGP, and proper posture or body mechanism
Study NCT02738515 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.75 % Boric Acid
Description: After Scaling and Root Planing placement of 0.75% Boric Acid gel in Mandibular degree 2 Furcation defect.
Study NCT02738515 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After Scaling and Root Planing placement of Placebo gel in Mandibular degree 2 Furcation defect.
Study NCT01761188 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ablation
Description: electrophysiology substrate mapping is the critical difference between both groups
Study NCT01618591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose rifaximin 1650 mg
Description: Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Study NCT01618591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose azithromycin 500 mg
Description: Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Study NCT00609622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
Study NCT04049227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care hysterectomy
Study NCT00594724 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
Study NCT02483871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Study NCT01618591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose levofloxacin 500 mg
Description: Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Study NCT01618591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose azithromycin 1000 mg plus loperamide
Description: Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
Study NCT00609622 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
Study NCT00609622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.
Study NCT00609622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFOX6
Description: FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m\^2 + leucovorin 400 mg/ m\^2 (or 200 mg/ m\^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m\^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m\^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
Study NCT01618591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single dose azithromycin 1000 mg plus placebo
Description: Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
Study NCT03974906 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Applying goal-directed fluid therapy by continuous hemodynamic monitoring system (LiDCO）
Description: Applying continuous hemodynamic monitoring system ( LiDCO) to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
Study NCT05527522 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: nutritional and educational intervention
Description: individualized diet plus educational intervention with/without nutritional supplements
Study NCT05527522 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: standard practice
Description: The patients received the usual treatment and clinical practice
Study NCT00886990 — intervention group
Intervention type: DRUG
Intervention: ritonavir-boosted PI-based second line treatments
Description: single PI boosted by low dose ritonavir
Study NCT05527522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: standard practice
Description: The patients received the usual treatment and clinical practice
Study NCT00918307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Day 1 to day 3 : 0.5 mg daily ; Day 4 to day 7 : 0.5 mg twice daily ; Day 8 to week 12 : 2 x 0.5 mg twice daily